Latest Insider Transactions at Incyte Corp (INCY)
This section provides a real-time view of insider transactions for Incyte Corp (INCY). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of INCYTE CORP to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of INCYTE CORP's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jul 03
2025
|
Barry P Flannelly EVP & General Manager US |
SELL
Open market or private sale
|
Direct |
10,903
-21.53%
|
$741,404
$68.15 P/Share
|
|
Jul 03
2025
|
Vijay K Iyengar EVP, GMAPPS |
SELL
Open market or private sale
|
Direct |
8,617
-9.7%
|
$585,956
$68.16 P/Share
|
|
Jul 02
2025
|
Paula J Swain EVP, Human Resources |
SELL
Payment of exercise price or tax liability
|
Direct |
6,285
-5.86%
|
$427,380
$68.17 P/Share
|
|
Jul 02
2025
|
Sheila A. Denton EVP & General Counsel |
SELL
Open market or private sale
|
Direct |
599
-2.21%
|
$40,732
$68.61 P/Share
|
|
Jul 02
2025
|
Sheila A. Denton EVP & General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
599
+2.16%
|
$34,742
$58.06 P/Share
|
|
Jul 02
2025
|
Barry P Flannelly EVP & General Manager US |
SELL
Payment of exercise price or tax liability
|
Direct |
9,055
-15.17%
|
$615,740
$68.17 P/Share
|
|
Jul 02
2025
|
Christiana Stamoulis EVP & Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
11,589
-8.98%
|
$788,052
$68.17 P/Share
|
|
Jul 02
2025
|
Steven H Stein EVP & Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
12,714
-10.16%
|
$864,552
$68.17 P/Share
|
|
Jul 02
2025
|
Thomas Tray Principal Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
897
-4.08%
|
$60,996
$68.17 P/Share
|
|
Jul 02
2025
|
Herve Hoppenot Special Advisor to the CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
42,769
-7.51%
|
$2,908,292
$68.17 P/Share
|
|
Jul 02
2025
|
Vijay K Iyengar EVP, GMAPPS |
SELL
Payment of exercise price or tax liability
|
Direct |
6,809
-12.82%
|
$463,012
$68.17 P/Share
|
|
Jul 02
2025
|
William Meury Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
36,101
+50.0%
|
-
|
|
Jun 30
2025
|
Baker Bros. Advisors LP |
BUY
Grant, award, or other acquisition
|
Indirect |
984
+0.01%
|
-
|
|
Jun 30
2025
|
Paul J Clancy Director |
BUY
Grant, award, or other acquisition
|
Direct |
361
+1.55%
|
$24,548
$68.1 P/Share
|
|
Jun 30
2025
|
Mohamed Khairie Issa EVP, Head of US Oncology |
BUY
Grant, award, or other acquisition
|
Direct |
27,812
+26.67%
|
-
|
|
Jun 30
2025
|
Edmund Harrigan Director |
BUY
Grant, award, or other acquisition
|
Direct |
367
+1.77%
|
$24,956
$68.1 P/Share
|
|
Jun 26
2025
|
Herve Hoppenot Special Advisor to the CEO |
BUY
Grant, award, or other acquisition
|
Direct |
6,016
+1.05%
|
-
|
|
Jun 10
2025
|
Jean Jacques Bienaime Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,518
+10.78%
|
-
|
|
Jun 10
2025
|
Jacqualyn A Fouse Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,518
+11.53%
|
-
|
|
Jun 10
2025
|
Otis W Brawley Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,518
+18.29%
|
-
|
|
Jun 10
2025
|
Edmund Harrigan Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,518
+11.21%
|
-
|
|
Jun 10
2025
|
Susanne Schaffert Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,518
+25.42%
|
-
|
|
Jun 10
2025
|
Susanne Schaffert Director |
SELL
Payment of exercise price or tax liability
|
Direct |
849
-14.84%
|
$59,430
$70.07 P/Share
|
|
Jun 10
2025
|
Paul J Clancy Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,518
+10.03%
|
-
|
|
Jun 10
2025
|
Baker Bros. Advisors LP |
BUY
Grant, award, or other acquisition
|
Indirect |
5,036
+0.05%
|
-
|
|
Jun 10
2025
|
Katherine A High Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,518
+15.88%
|
-
|
|
Jun 03
2025
|
Sheila A. Denton EVP & General Counsel |
SELL
Open market or private sale
|
Direct |
1,795
-6.34%
|
$122,060
$68.0 P/Share
|
|
Jun 03
2025
|
Sheila A. Denton EVP & General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
1,795
+5.96%
|
$104,110
$58.06 P/Share
|
|
Jun 02
2025
|
Thomas Tray Principal Accounting Officer |
SELL
Open market or private sale
|
Direct |
651
-2.87%
|
$41,664
$64.88 P/Share
|
|
May 30
2025
|
Thomas Tray Principal Accounting Officer |
SELL
Open market or private sale
|
Direct |
963
-4.08%
|
$62,595
$65.71 P/Share
|
|
Apr 01
2025
|
Paula J Swain EVP, Human Resources |
BUY
Grant, award, or other acquisition
|
Direct |
22,141
+9.83%
|
-
|
|
Apr 01
2025
|
Steven H Stein EVP & Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
58,165
+20.33%
|
-
|
|
Apr 01
2025
|
Christiana Stamoulis EVP & Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
37,568
+13.63%
|
-
|
|
Apr 01
2025
|
Michael James Morrissey EVP, Head of Tech. Operations |
BUY
Grant, award, or other acquisition
|
Direct |
4,649
+5.12%
|
-
|
|
Apr 01
2025
|
Vijay K Iyengar EVP, GMAPPS |
BUY
Grant, award, or other acquisition
|
Direct |
22,141
+19.14%
|
-
|
|
Apr 01
2025
|
Barry P Flannelly EVP & General Manager US |
BUY
Grant, award, or other acquisition
|
Direct |
26,135
+20.01%
|
-
|
|
Apr 01
2025
|
Herve Hoppenot Special Advisor to the CEO |
BUY
Grant, award, or other acquisition
|
Direct |
66,899
+10.61%
|
-
|
|
Mar 31
2025
|
Baker Bros. Advisors LP |
BUY
Grant, award, or other acquisition
|
Indirect |
974
+0.01%
|
-
|
|
Mar 31
2025
|
Edmund Harrigan Director |
BUY
Grant, award, or other acquisition
|
Direct |
363
+2.04%
|
$21,780
$60.55 P/Share
|
|
Mar 31
2025
|
Paul J Clancy Director |
BUY
Grant, award, or other acquisition
|
Direct |
358
+1.75%
|
$21,480
$60.55 P/Share
|
|
Mar 25
2025
|
Matteo Trotta EVP, GM, Dermatology US |
SELL
Payment of exercise price or tax liability
|
Direct |
537
-5.13%
|
$33,294
$62.08 P/Share
|
|
Mar 14
2025
|
Barry P Flannelly EVP & General Manager US |
SELL
Open market or private sale
|
Direct |
19,807
-12.52%
|
$1,327,069
$67.8 P/Share
|
|
Mar 04
2025
|
Sheila A. Denton EVP & General Counsel |
SELL
Open market or private sale
|
Direct |
599
-2.26%
|
$41,331
$69.99 P/Share
|
|
Mar 04
2025
|
Sheila A. Denton EVP & General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
599
+2.21%
|
$34,742
$58.06 P/Share
|
|
Feb 26
2025
|
Sheila A. Denton EVP & General Counsel |
SELL
Open market or private sale
|
Direct |
14,069
-19.4%
|
$1,041,106
$74.08 P/Share
|
|
Feb 26
2025
|
Sheila A. Denton EVP & General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
9,574
+19.34%
|
$555,292
$58.06 P/Share
|
|
Jan 31
2025
|
Lee Heeson EVP, Head of Incyte Intl |
BUY
Grant, award, or other acquisition
|
Direct |
6,331
+16.19%
|
-
|
|
Jan 31
2025
|
Michael James Morrissey EVP, Head of Tech. Operations |
BUY
Grant, award, or other acquisition
|
Direct |
10,552
+11.46%
|
-
|
|
Jan 21
2025
|
Michael James Morrissey EVP, Head of Tech. Operations |
SELL
Payment of exercise price or tax liability
|
Direct |
429
-0.6%
|
$31,317
$73.47 P/Share
|
|
Jan 21
2025
|
Steven H Stein EVP & Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
12,352
-15.57%
|
$889,344
$72.69 P/Share
|